Enhancing Translation of PKMYT1 Targeting: In Vivo & In Vitro Strategies for Maximizing Efficacy & Patient Impact
Time: 10:30 am
day: Day Two
Details:
- Conducting comparative analysis of the in vitro profile of Evariste’s preclinical candidate PKMYT1 inhibitor, EVT-3023
- Analyzing of the extent to which PKMYT1 is responsible for control of pCDK1 levels in various in vitro and in vivo models
- Exploring translation of a novel biomarker for sensitivity to PKMYT1 inhibition
